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Cells within a tissue continuously interact to coordinate normal tissue functions and maintain homeostasis. Gap junctional communication
(GJC), mediated by the connexin protein family, allows this type of intercellular crosstalk resulting in synchronized and cooperative tissue
behavior such as cardiac contraction. In cancer, loss of these types of cell:cell interactions has been shown to facilitate tumorigenesis and enable
the autonomous cell behavior associated with transformed cells. Indeed, many human tumor lines demonstrate deficient or aberrant GJC and/or
loss of connexin expression. Restoration of exogenous connexin expression/GJC function is correlated with increased cell growth control both in
vitro and in vivo. In support of this growth regulatory hypothesis, decreased connexin expression has been observed in situ in early human
neoplasia of various organs. Additionally, genetically engineered mice lacking particular connexins (Connexins 32 or 43) exhibit increased
susceptibility to radiation and chemically-induced liver and/or lung tumorigenesis. These studies strongly suggest that connexins and GJC serve a
tumor suppressor role. Consistent with this proposed role, in a model cell culture system, retinoids and carotenoids up-regulate Connexin43
(Cx43) expression in direct proportion to their ability to suppress carcinogen-induced neoplastic transformation. Here, we discuss the important
role of connexins and GJC in tumorigenesis and suggest the possibility of connexins as potential anti-oncogenic targets for chemoprevention and/
or chemotherapy.
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cancer models
The discovery by Loewenstein and Kanno in 1966 that
cultured fibroblasts were electrically coupled when in contact
was the first demonstration of the phenomenon of gap
junctional communication (GJC) [1]. Loewenstein’s group
later showed that malignantly transformed fibroblasts were
deficient in this ability to communicate and that activation of a
temperature-sensitive src oncogene in communicating fibro-
blasts led to a rapid inhibition of junctional coupling and loss
of growth control [2]. These observations led to the hypothesis
of growth control through GJC [3]. In this model, GJC
produces gradients of growth control signals throughout an
organ, or a cell monolayer, allowing cells to control their
population density. A large body of evidence now exists thatFig. 1. Gap junctional intercellular communication (GJC) mediated by connexin prot
or connexon. Adjoining cells each contribute one connexon to form a complete gap
of this channel are regulated to a large extent via phosphorylation of the cytoplasmimplicates loss of GJC as an important event in carcinogenesis
and thus identifies connexins as potential targets for prevention
and possibly therapy. As discussed elsewhere in this book, gap
junctions are water-filled pores formed by the docking of two
hemi-channels (connexons), contributed by each of the
adjoining cells (see Fig. 1). GJC allows for direct exchange
between neighboring cells of small hydrophilic molecules and
ions less than 1–2 kDa in size including metabolites and
messengers such as sodium, potassium, calcium, cAMP/cGMP,
ADP/ATP and inositol 1,4,5-triphosphate resulting in the
metabolic and electric coupling of cells. Connexin function is
highly regulated at the level of transcription, translation,
processing, gating and protein/channel turnover. Phosphoryla-
tion of multiple serines, threonines and tyrosines, predomi-
nantly in the cytoplasmic tail, appears to contribute to the
orchestration of these various regulatory steps for severaleins. Hexameric arrangements of connexin monomers comprise a hemi-channel
junction channel. For several connexin types, the assembly, gating and turnover
ic tail by various cellular kinases including: src, PKC and MAPK.
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that an additional function of this coupling is to control cell
proliferation which when perturbed can accelerate the process
of carcinogenesis and when restored can suppress indices of
malignancy.
2. Role of GJC and connexins in dysplasia and advanced
cancer
Numerous studies have demonstrated that human cancers are
deficient in GJC either as a result of downregulated expression
of connexins, altered trafficking to the cell membrane or the
inability to form functional junctions. This subject has been
recently reviewed [4]. While most studies have involved human
tumor cell lines, some have examined primary excised tumors,
either by immunohistochemistry or by functional analysis.
These studies included lung carcinomas of various pathologies,
renal carcinomas, endometrial carcinomas, breast carcinomas,
gliomas, cervical carcinomas and prostate carcinomas (Fig. 2).
While there have been reports that melanoma tumor types
continue to express connexins, this is accompanied by an altered
ability for heterotypic communication; the normal communica-
tion with keratinocytes is blocked and is substituted by
communication with fibroblasts [5]. This consistent lack of
normal GJC in tumor cells strongly suggests that in order to
progress, developing tumors must isolate themselves from the
direct influence of surrounding normal cells. In this respect,
connexins behave similarly to the majority of tumor suppressor
genes whose expression or function must also be abrogated to
allow carcinogenic progression (reviewed in [6]).
Changes in GJC during carcinogenesis have been exten-
sively examined in skin. Human and rodent skin expressFig. 2. Immunohistochemical detection of Cx43 in human cervical biopsies. Red
staining is indicative of Cx43 immunoreactivity. Panel A, normal cervical
epithelia. Panel B, higher magnification of panel A sample. Panel C, cervical
dysplasia (CIN-2). Panel D, higher magnification of panel C sample. Note
decreased Cx43 immunoreactivity in dysplastic tissue in panels C and D
compared to panels A and B. Reproduced from King et al. [49] with permission.multiple connexin types with Cx43 and Connexin26 (Cx26)
being predominant. In mouse epidermis, Cx26 protein is
localized to differentiated, upper layers (spinous and granulosa)
with Cx43 protein found in the less differentiated, basal
keratinocyte cell layer [7–9]. In contrast, human epidermis
exhibits an opposite connexin localization with Cx43 protein in
the upper, differentiated layers (spinous and granulosa)
whereas in basal keratinocytes Cx26 is expressed at lower
levels. Alterations in Cx43 and Cx26 mRNA and protein levels
as well as in localization have been shown in several studies
employing multi-stage mouse skin tumorigenesis protocols
including 7,12-dimethylbenzanthracene (DMBA) or N-methyl-
NV-nitro-guanidine as initiators and 12-O-tetradecanoylphor-
bol-13-acetate (TPA) as a tumor promoter [7–9]. Although
Cx43 and Cx26 protein levels have been reported to remain
unchanged in hyperplastic skin, two studies observed increased
Cx43 and Cx26 protein levels in papillomas, a pre-neoplastic
lesion, which was accompanied by abnormal co-localization
[7,9]. In contrast, both Cx43 and Cx26 message levels were
drastically decreased in squamous cell carcinomas. As will be
discussed later, retinoic acid, a cancer preventive agent in skin,
strongly upregulates expression of Cx43 [10] and Cx26 in
human skin [11]. Interestingly, no increase in skin tumor
incidence or multiplicity was detected in genetically engineered
Cx43 heterozygous mice exposed to a multi-stage skin
carcinogenesis protocol (DMBA/TPA) [12]. While in humans
there have been no reports linking connexin mutations with
skin neoplasia, one study reported that mutations in con-
nexin31 are associated with epithelial hyperplasia [13].
3. Restoration of GJC decreases the transformed phenotype
Using gene transfer technology, numerous studies have
restored connexin expression to immortalized and transformed
cell lines lacking connexin protein expression and observed
varying degrees of cellular growth control. Responses ranged
from a complete lack of effect to loss of tumorigenicity both in
culture and in vivo. The variation in connexin-related effects
may be due to intrinsic cell properties (mutations, etc.), clonal
variation and heterogeneity (control vector-clone compared to
exogenous expressing-clone), cell type-connexin type specific-
ity or even the assay type and its relevance towards the particular
growth characteristic influenced by connexin expression/GJC
function.
Studies demonstrating alterations in cell logarithmic growth
or saturation density suggest a role for several Cxs in regulation
of cell growth parameters. One such study evaluated alterations
in cell cycle regulatory proteins following re-expression of Cx43
in a canine kidney epithelial cell line [14]. In this study, altered
protein levels of certain cyclins and CDKs were observed
suggesting that Cx43 expression influenced cell cycle status
either directly or indirectly. However, to date few definitive
mechanisms for GJC/connexin-mediated cell cycle regulation or
influence on tumor promotion or progression have been
elucidated. One exception is the recent implication of Cx43 in
the regulation of the E3-ligase Skp2 that directly mediates
degradation of the cell cycle regulatory protein p27Kip1 [15,16].
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line correlated with increased p27Kip1 levels. This is in
agreement with a previous study that observed increased
p27Kip1 levels and enhanced growth control in a lung carcinoma
and a liver carcinoma cell line engineered to re-express Cx43
and Cx32 respectively [17]. Increased p27Kip1 levels have been
shown to regulate CDK/cyclin activity resulting in cellular
growth arrest in late G1 phase. In humans decreased p27Kip1
expression is used as a clinical prognostic for decreased survival
in a multitude of tumor types and in a genetically deficient
mouse model results in increased tumorigenesis [18,19].
Increased cellular proliferation and/or loss of cell cycle
regulation correlate with increased frequency of mutation
fixation within the genome. As cells accrue DNA damage,
control of cell cycle progression is critical to enable cellular
DNA repair mechanisms to correct mutations. Loss of connexin
expression/function may allow a bypass of normal cell arrest
pathways resulting in diminished DNA damage repair and
increased mutational frequency. In fact, one such study linked
increased mutation frequency in Cx43-negative cells compared
to Cx43-positive cell lines [20]. This suggests that the decreased
connexin expression observed in early human dysplasia would
accelerate the process of tumor progression.
Although connexin expression is lost in a majority of tumor
cells, to our knowledge in only one case has a mutation within
a connexin gene been reported [21]. Several studies have
shown that alterations in connexin gene promoter methylation
are associated with gene silencing [22]. One clinical study
found promoter methylation strongly negatively correlated with
Cx43 expression and decreased with distance from the primary
tumor [23]. We have shown re-expression of Cx43 following
treatment of HeLa cells with 5-aza-cytidine to reduce DNA
methylation [24]. Additionally, observations on tumor cell lines
suggest that histone deacetylation also results in connexin gene
repression [22,25]. The concept of employing DNA demethy-
lating agents or modifiers of histone acetylation status to
counteract connexin gene repression is an interesting chemo-
therapeutic possibility which is discussed below.
Several studies have implicated viral and cellular oncogenes
in altered GJC function [22]. Specifically, viral infection or
transfection of viral encoded oncogenes, such as v-src and
polyomavirus middle T-antigen into GJC-competent cells
resulted in decreased GJC. In the case of v-src, oncogene-
mediated tyrosine phosphorylation on the carboxy tail of Cx43
has been shown to decrease GJC channel function [26]. Several
studies have demonstrated a link between Cx43 expression and
a well studied oncogenic pathway, the Wnt signaling pathway.
Investigators utilizing the intestinal tumor mouse model (min,
containing a mutated adenomatous polyposis coli gene, APC)
observed decreased Cx32-mediated GJC in Paneth cells of the
intestine and in contrast increased Cx43 levels in stromal
components of intestinal adenomas [27]. Additional studies
showed that Cx43 gene expression can be upregulated via
activation of the Wnt pathway and that the Cx43 promoter is
responsive to h-catenin transcriptional activation [28,29]. Here,
one possibility is that the APC protein plays a role in regulation
of Cx32 expression in the intestine, possibly by controlling h-catenin levels/activity. It is also possible that APC deficiency
allows increased cell proliferation and increased mutation
frequency resulting in loss of Cx32 expression/GJC function.
4. Genetically engineered connexin mouse strains
Genetically engineered knockout mouse strains (KO mice)
lacking specific connexins have recently yielded information
regarding the importance of specific connexins in development
as well as normal physiology for several tissue types (see
[30,31] for review). For example, Cx32-KO mice display
compromised liver function as revealed by defective propaga-
tion of sympathetic nerve stimulation [32], altered initiation
and termination of DNA synthesis during post-hepatectomy
regeneration [33] and defective signaling due to decreased
propagation of inositol tri-phosphate via GJC channels [34].
These mice also exhibit altered pancreatic function, increased
neural progenitor pools and peripheral nerve degeneration in
older aged animals reminiscent of human CMTX [35]. Female
Cx37-KO mice fail to ovulate and are therefore infertile
apparently because of impaired junctional interactions between
oocytes and surrounding granulosa cells leading to reciprocal
impaired maturation [36]. Cx26-KO and Cx45-KO mice die in
utero and Cx43-KO mice die peri-natally due to heart
malformation [30,31]. This Cx43-KO effect has been shown
to be the result of altered migration of neural crest cells during
embryogenesis [37]. Interestingly, heterozygous Cx43-KO
mice and transgenic mice over-expressing Cx43 also exhibit
cardiac abnormalities further supporting the importance of
regulated connexin expression [38,39]. Cx40-KO mice exhibit
heart conduction abnormalities implicating a second connexin
type in cardiac development and function [30]. These disparate
phenotypes not only show the diversity of the expression
pattern of connexins, but also illustrate the varying functions
conducted by connexins and GJC in different tissues.
Mouse ‘‘knock in’’ experiments, in which one connexin
isotype is specifically replaced with another, have shown that
particular connexins play distinct roles in specific cellular
processes. In a study where Cx43 was replaced by Cx32 or
Cx40, the resulting mice survived and exhibited altered cardiac
defects specific to Cx32 replacement, however both mouse
strains also demonstrated a variety of altered developmental
effects in several other tissues [40]. Recently, replacement of
wild-type Cx43 with a truncated version (K258Stop) lacking
the carboxy-terminal, cytoplasmic tail region resulted in peri-
natal lethality due to an epidermal barrier defect but not due to
any heart defect as seen with Cx43-KO mice [41]. This
epidermal integrity failure may be due to altered Cx43 protein
trafficking, processing or degradation as the C-terminal region
has been shown to contain multiple sites for phosphorylation
and protein–protein interaction.
5. Cx32-KO and Cx43 heterozygous mice are more
sensitive to carcinogens
Although many of the connexin KO mouse strains created
have demonstrated altered development and physiology, only
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increased susceptibility to tumorigenesis. However, it is worth
noting that several KO strains (such as Cx26, Cx43 (nullizy-
gous) and Cx45) exhibit embryonic or neo-natal lethality
preventing the proper evaluation of connexin-related effects on
long-term carcinogenesis [30]. Presumably, evaluation of
existing or soon-to-be constructed mouse strains, in which
tissue-specific ablation of these critical connexins can be
achieved, would allow survival and enable investigation of
cancer susceptibility.
Cx32-KO mice exhibit increased liver tumor incidence,
multiplicity, size and progression (carcinoma) following
exposure to chemical carcinogens (DEN, diethylnitrosamine)
and radiation (X-ray) implicating Cx32 specifically in hepatic
tumor promotion/tumorigenesis [42–44]. Indeed, this in-
creased susceptibility may be related to the increased hepato-
cyte proliferation previously reported for this mouse model
[42–44]. Mechanistically, a higher percentage of liver tumors
from chemical and radiation-induced Cx32-KO mice exhibited
MAPK-pathway activation compared to wild-type controls
[44]. This observation suggests differential generation of
mutations or selection of tumors occurs in the absence of
Cx32-mediated GJC.
One carcinogenesis study showed that Cx32 also acts as a
tumor suppressor in mouse lung (Fig. 3) [45]. Exposure to
radiation or a chemical carcinogen (DEN) resulted in an
increased tumor incidence, multiplicity and progression. This
enhanced sensitivity may be due in part to the enhanced
alveolar cell proliferation observed in non-transformed Cx32-
KO lung tissue, similar to that observed in Cx32-KO liver [45].
Interestingly, an increased percentage of lung tumors from
Cx32-KO mice exhibited MAPK pathway activation similar toFig. 3. Cx32-KO mice exhibit increased lung tumorigenesis in response to diethylni
display 2.4-fold increase in tumor incidence, increased average multiplicity and
carcinomas from Cx32-KO mice. Incidence=number of mice with lung tumors/to
number of mice with lung tumors. Adenoma/Carcinoma percents are calculated asthat observed in Cx32-KO liver. Increased MAPK activation in
both tissues suggests a modified or preferentially selected
oncogenic pathway altered by the loss of Cx32-mediated GJC
that is possibly held in common importance in both liver and
lung tissue. Assuming a similar MAPK bias in GJC-deficient
human neoplasia, the remote possibility of targeting GJC-
deficient, MAPK-activated tumors using MAPK inhibitors is
intriguing.
In another study, Cx32-KO mice exposed to benzene
exhibited increased pulmonary pneumotoxicity but no increase
in lung carcinogenesis was observed [46]. However, strain
background, different carcinogen type and, as the authors
admit, a small number of animals in the benzene-exposed
tumor group may have contributed to discrepancies between
these studies. In addition to these Cx32-related lung effects,
one study observed increased lung tumor multiplicity and
tumor progression (based on categorization into solid or
papillary morphology) in KO mice heterozygous for Cx43
which is also expressed in the lung, [47]. The separate or
combined contributions of Cx32 and Cx43, or possibly other
connexins that are expressed in lung (e.g. Cx37/Cx40), to
mouse lung tumorigenesis remain to be established. Further
investigations utilizing double KO mice lacking both Cx32/
Cx43 or conditional, lung-specific Cx43-KO mice will
hopefully shed light on the exact contributions of both
connexins to normal lung physiology and lung tumor character.
In both cases of KO mouse-associated increased suscepti-
bility to tumorigenesis, it is worth noting that induction by
exposure to a tumor initiator was required. Cx32-KO and
Cx43-heterozygous mice do not demonstrate any increases in
spontaneous liver or lung tumorigenesis [43–45]. An initial
report of increased spontaneous liver tumors in the Cx32-KOtrosamine (DEN) treatment (9 month study duration). Panel A, Cx32-KO mice
increased tumor progression (carcinoma:adenoma ratio); Panels B+C, lung
tal number of mice. Average multiplicity= total number of lung tumors/total
percent of total tumors detected.
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group [43]. The lack of increased spontaneous tumor formation
strongly implicates GJC in tumor promotion and/or progression
in these tissues and not tumor initiation. Again, these
observations in situ correlate with the observed role of GJC
in culture experiments where loss of GJC-mediated interactions
with normal, growth-controlled counterparts allowed autono-
mous growth and increased neoplastic potential [22]. Such a
tumor promotional aspect to GJC-mediated tumor suppression
denotes connexin upregulation as a potential chemoprevention
target. The inhibitory role of GJC in liver tumor promotion is
further emphasized by the observation that Cx32-KO mice are
no longer responsive to the promoting effects of Phenobarbital,
previously shown to inhibit Cx32-mediated GJC in this organ.
In DEN-treated Cx32-KO mice, Phenobarbital failed to
enhance production of both preneoplastic foci and hepatomas
indicating that GJC impacts events early in the carcinogenic
process [48].
6. Restoration of connexin expression in tumor cells reduces
their neoplastic potential
Over the last several decades, numerous laboratories have
employed constitutive gene expression systems to restore
connexin/GJC function in GJC-deficient tumor cell lines
resulting in variable re-establishment of several aspects of cell
growth control including; decreased logarithmic growth and
saturation density, decreased growth in heterologous culture
with growth-controlled cells, decreased anchorage-independent
growth as well as diminished in vivo tumor formation for aFig. 4. Inducible HeLa lines demonstrate regulable Cx43 protein expression (Weste
dye spread from microinjected cells to neighboring cells in an induced monolayer (
uninduced monolayer (panel B). Induced cells attenuated tumorigenicity in xenogr
(panels D/Clone 1 and E/Clone 2). Red dots represent mean tumor volume of indu
Numbers at end of curve represent number of detected tumors/total number of injec
mean tumor volumes. Reproduced from King et al. [49] with permission.variety of cell types [22]. To better define connexin function in
the absence of clonal heterogeneity issues, several studies have
utilized inducible gene expression systems. Two such human
tumor cell lines (HeLa, cervical carcinoma and HT-1080,
fibrosarcoma) containing inducible Cx43 gene constructs
demonstrated decreased neoplastic potential following restora-
tion of Cx43/GJC function both in vitro (decreased anchorage-
independent growth) and in vivo (decreased xenograft tumor
formation) (Fig. 4) [49,50]. These studies all underscore the
importance of connexins and GJC in normal cell biology and
their loss in increased neoplastic potential. Although more
advanced aspects of the neoplastic phenotype were diminished
following GJC restoration in these cell lines, many in vitro
measures of growth were unaffected. This may simply be a
consequence of the prior evolution of these cell lines within the
in vitro environment resulting in a loss of responsiveness to
GJC-mediated signaling.
Additionally, it is worth noting that while restoration of
connexin expression within the context of certain transformed
cell types is associated with decreased indices of neoplasia, the
extent of connexin influence is clearly limited. For example,
while inducible expression of Cx43 in both HeLa and HT-1080
cell lines resulted in decreased xenograft tumorigenicity, tumors
were nonetheless capable of forming in the presence of Cx43 (no
loss of Cx43 expression was observed with HT-1080 tumors
explanted from induced mice). Several complicating factors
should be considered with respect to connexin growth control.
Loss of connexin expression in fully transformed cells lines,
assuming connexin loss is an early oncogenic event as it appears
to be, may be accompanied or followed by multiple mutations inrn immunodetection, panel A) and increased GJC seen as increased fluorescent
panel C) compared to no dye transfer from numerous microinjected cells in an
aft mouse experiments (nude mice) for two individual inducible HeLa clones
ced tumors and black dots represent mean tumor volume of uninduced tumors.
tions. P values represent statistical differences between uninduced and induced
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restoration of exogenous connexin expression results in only
partial or no alteration of tumor growth capacity. An alternate
view is that a particular connexin or connexins, in general, are
capable of regulating only certain aspects of tumor progression
(such as cellular density) and therefore restoration effects are
limited to these specific characteristics.
Several studies have documented evidence that connexin
function is tissue-type specific. As connexin type expression
patterns are variable, it is possible that a particular connexin
may function as a tumor modulating protein in one or several
specific cell types and not in others. This may be due to
expression restrictions or intracellular regulatory mechanisms
(absence or presence of distinct signaling or responsive
pathways). Clearly, interaction with the external environment
as well as surrounding cell types increases the complexity of
evaluating specific connexin function.
In addition to tumor promotion and oncogenic pathway
activation, another important facet of tumor progression is
vascularization and intravasation resulting in tumor expansion
and metastasis. Recently, one group observed an increase in the
pro-angiogenic factor vascular endothelial growth factor
(VEGF) and a decrease in the anti-angiogenic factor thrombos-
pondin-1 (TSP-1) following Cx43 siRNA knockdown in a
human mammary tumor cell line [51]. These results possibly
explain the lack of in vitro growth changes in contrast to the in
vivo effects seen following inducible expression of exogenous
Cx43 in the engineered human cell lines described earlier
[49,50].
Confusingly, several studies have presented conflicting data
suggesting that connexin loss or sustained connexin expression
may contribute to certain invasive properties of transformed
cell lines. For some tumor types, particularly melanoma, the
concept that the malignant potential is inversely correlated with
GJC capacity appears to be an oversimplification. Studies of
human melanoma have shown that while the capacity to
communicate with keratinocytes is lost with malignant
transformation, communication with fibroblasts is gained. This
has been associated with a shift in cadherin expression profiles
from E-cadherin, also expressed in keratinocytes, to N-cadherin
expressed in fibroblasts. This shift in junctionally coupled
partners was not accompanied by changes in overall expression
of Cx43 in the melanoma cells [52]. In mouse melanoma cells,
Cx26-mediated GJC with endothelial cells was associated with
a high incidence of metastasis, while ectopic expression of
Cx26 in a weakly metastatic cell line enhanced its ability to
communicate with endothelial cells and increased its metastatic
capacity [53]. It may be that changes in junctional partners may
liberate melanoma cells from homeostatic controls, in this case
mediated by keratinocytes, while at the same time allowing
communication with endothelial cells and fibroblasts which
may donate nutrients resulting in enhanced metastasis. Similar
increases in metastatic or invasive ability have been documen-
ted for glioma [54] and HeLa cells [55] transfected with Cx43.
It may be that these cell lines have lost the capacity to respond
to junctionally transferred signals but may still benefit from
nutrient transfer from communicating, non-transformed cells.In any event, there is a preponderance of data implicating
altered connexin/GJC function in carcinogenesis in situ. The
possibility of induction of connexin/GJC in combination with
certain angiogenesis inhibitors or metalloproteinase inhibitors
may enhance chemotherapeutic value in the clinic.
7. Cancer prevention and the role of connexins
Prevention, it is said that prevention is better than cure and
this is never more true than in the case of cancer whose
successful treatment in many instances has proved elusive.
Opportunities for prevention occur at three distinct phases in
the process of carcinogenesis; these have been termed primary,
secondary and tertiary prevention (reviewed in [56]). Primary
prevention concerns limiting exposure to the carcinogenic
stimulus, be it tobacco, ionizing radiation or industrial
chemicals. If the carcinogenic stimulus is known, this can be
an effective strategy, as can be demonstrated by the current
decrease in lung cancer rates following reduction in tobacco
consumption. This aspect of cancer prevention will not be
discussed further here. Chemoprevention, the use of chemical
agents to prevent cancer development, can be applied to the
secondary and tertiary forms of prevention. Secondary preven-
tion applies to the use of strategies to prevent the formation of
DNA mutations following exposure to chemical carcinogens.
This has been demonstrated experimentally by the induction of
enzymatic detoxification mechanisms which serve to diminish
the formation of DNA-reactive metabolites. Tertiary prevention
encompasses strategies which seek to prevent the further
progression of cells (so-called initiated cells) possessing initial
mutations which predispose them to developing subsequent
mutations leading to cellular transformation. It is in this phase
of carcinogenesis that connexins appear to play a role in
prevention; a phase in which we have shown cancer preventive
agents to cause upregulated expression of Cx43.
As discussed earlier, most human tumor cells are deficient in
GJC, primarily as a consequence of downregulated expression
of connexin genes. We and others have shown that this event
occurs early during the carcinogenic process, i.e., during the
progression of initiated cells to fully established malignant
cells. In the uterine cervix, we have shown Cx43 expression to
be strongly downregulated in dysplastic epithelium, presum-
ably as a consequence of infection with HPV, the etiologic
agent of most cervical carcinomas. A similar phenomenon has
been demonstrated in oral leukoplakia, a preneoplastic lesion
formed as a consequence of exposure to tobacco products.
Similarly in the liver, in which Cx32 is predominantly
expressed, progressive downregulation of expression correlates
with progressive development of the neoplastic phenotype
[57,58]. Further underlying the crucial role of GJC in limiting
aberrant proliferation are the results obtained in the Cx32-KO
mouse studies discussed above, which demonstrate greater
susceptibility to carcinogen-induced neoplasia. Susceptible
tissues exhibit increased rates of proliferation [42,45], an
observation consistent with the widely accepted role of
aberrant proliferation in the fixation of carcinogen-induced
mutations associated with the subsequent progression of such
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strategies to prevent downregulated expression of connexins in
initiated cells would serve to decrease their proliferation and
delay their progression to neoplasia. This, while not eliminat-
ing the formation of initiated cells, would nevertheless be an
effective prevention strategy if this delay could be extended to
decades. The topic of connexins in cancer prevention and
therapy was last reviewed in 2002 [59].
8. Retinoids and carotenoids as cancer chemopreventive
agents
Retinoids are compounds which include vitamin A and
synthetic vitamin A analogs. These activate nuclear retinoid
receptors and serve to maintain normal growth, differentiation
and immune function. Carotenoids are a group of plant-derived
pigments comprised of members that can either be centrally
cleaved to yield two molecules of vitamin A (pro-vitamin A,
such as h-carotene) or those that cannot due to a lack of the h-
ionone ring necessary for formation of retinoids (non-pro-
vitamin A, such as lycopene the red pigment in tomatoes) (Fig.
5). In experimental animals and cell culture models of
carcinogenesis, retinoids and both classes of carotenoid (pro-
vitamin A and non-pro-vitamin A) have been shown to inhibit
carcinogenesis. In clinical studies, retinoids have been shown
to be effective in the prevention of cervical [60] and oralFig. 5. Chemical structures of retinoic acid (A), pro-vitamin A-carotenoid h-car
disuccinate (CARDAXi, D) and astaxanthin diphosphate (E).cancers [61], however, their toxicity has so far eluded
successful widespread clinical application. For carotenoids, in
spite of abundant epidemiologic evidence for risk reduction
with increased consumption or increased blood levels of
carotenoids [62,63], intervention trials have yet to convincingly
show effectiveness. For example, high-dose supplementation
with h-carotene in the Physicians Health Study failed to show
protection against lung cancer in this relatively healthy group
of individuals [64]. However, when similar studies were
conducted in high-risk individuals who were currently smo-
kers, some of whom had also been exposed to asbestos, h-
carotene actually increased lung cancer rates [65]. In animal
models, this toxicity was shown to be a consequence of
decreased retinoic acid content and increased AP-1 signaling in
the smoke-exposed lungs [66]. Conversely, in head and neck
cancer, also a smoking-related disease, h-carotene has been
shown to reduce the incidence of leukoplakia, a premalignant
lesion [67]. It may be that the high partial pressure of oxygen in
the lung predisposes this organ to the pro-oxidant action of h-
carotene [68]. Additionally, the incidence of prostate cancer has
been inversely correlated with dietary lycopene [62]; to test this
association, two small clinical trials have been conducted in
prostate cancer patients scheduled for radical prostatectomy. In
both studies, there was evidence of increased apoptosis in
tumor tissue [69]; moreover, one of the studies documented an
increase in Cx43 expression [70]. The following discussionotene (B), non-pro-vitamin A-carotenoid lycopene (C), astaxanthin disodium
Fig. 6. Photomicrographs of 10T1/2 cells stained with Giemsa. Panel A, cell monolayer (M) showing the highly ordered and low density organization of cells; panel
B, edge of a transformed focus (TF) resulting from 24 h exposure to methylcholanthrene (MCA) 5 weeks prior to fixation.
T.J. King, J.S. Bertram / Biochimica et Biophysica Acta 1719 (2005) 146–160154will be limited to the effects of retinoids and carotenoids in
model cell culture systems.
The immortalized mouse embryonic fibroblast 10T1/2 cell
line was developed as an in vitro model of chemical
carcinogenesis. Cells are plated at low density and exposed
to chemical or physical carcinogens after which a small
proportion of cells, typically 1% of survivors, acquire the
characteristics of initiated cells and undergo neoplastic
transformation to form a transformed focus. This occurs
approximately 4 weeks after carcinogen exposure and repre-
sents clonal expansion to form a foci in the context of a
complete cell monolayer (Fig. 6) [71]. The colony size achieved
by initiated cells during this process of expansion is crucial to
the production of transformed foci; if the colony does not reach
approximately 1000 cells transformation is progressively
inhibited [72]. This inhibition we now believe is a conse-
quence of Cx43-mediated GJC between initiated cells and
surrounding non-initiated cells in the monolayer resulting in
decreased initiated cell proliferation. When retinoids or
carotenoids were added 7 days after the initiating event and
maintained for the remaining 4 weeks of the assay, a dose-
dependent decrease in transformation was observed which was
reversible upon drug removal [73,74]. This reversibility
demonstrates that these agents do not selectively eliminate
initiated cells but actually prevent their progression to
neoplasia.
9. Retinoids and carotenoids up-regulate Cx43 expression
and GJC in 10T1/2 cells
This chemopreventive ability of retinoids and carotenoids
not only directly correlates with their ability to increase GJC
among both normal and initiated cell types, but also
corresponds with their capacity to upregulate GJC between
the these two cell types [75,76]. We proposed a model where in
the control situation, initiated cells, situated centrally in a
colony of 1000 initiated cells, would be shielded from the
influence of surrounding normal cells. Conversely, cultures
treated with retinoids or carotenoids, with the enhanced GJC
caused by these agents, would increase transfer of signal
molecules from normal to centrally located initiated cells
thereby preventing aberrant proliferation and neoplastic pro-
gression. Upon removal of the chemopreventive agent, GJC
was shown to decrease to untreated levels thereby againeffectively shielding centrally located initiated cells from the
influence of surrounding normal cells. It is of interest that many
classes of tumor promoters, including Phenobarbital and TPA,
inhibit GJC [77]. That this activity of promoters to inhibit GJC
is directly related to their tumor promoting abilities is strongly
supported by the data referenced above, that Cx32-KO mice
are no longer responsive to Phenobarbital in mouse liver tumor
promotion experiments using the chemical carcinogen DEN
[78,79]. In the 10T1/2 mouse fibroblast cell line, TPA inhibits
Cx43 mediated GJC whereas treatment with retinoids counters
both this inhibition and its tumor promoting action [76]. These
studies strongly support the concept that an important action of
tumor promoters is to downregulate GJC.
10. Carotenoids induce Cx43 irrespective of pro-vitamin A
or antioxidant properties
At the time we were characterizing the cancer chemopreven-
tive properties of carotenoids, the only known common property
shared by these carotenoids was the ability to act as lipid-phase
anti-oxidants, a plausible mechanism for prevention. However,
when we examined the antioxidant activities of diverse
carotenoids in 10T1/2 cell cultures, we discovered that although
all carotenoids did indeed prevent oxidative damage, as
indicated by a decrease in the formation of thiobarbituric acid
reactive-substances (TBARS), this ability did not correlate with
their activities as inhibitors of transformation. Furthermore, the
non-carotenoid lipid-phase antioxidant a-tocopherol, was found
to be a very poor inhibitor of neoplastic transformation. Even at
concentrations of 104 M, 10-fold higher than that used for
carotenoids, it failed to induce Cx43 expression even though it
was the most effective inhibitor of TBAR formation [80]. Thus,
within the limits of this particular lipid-phase oxidation damage
assay, it appeared that while all carotenoids were indeed
antioxidants, this did not appear to be the major factor
responsible for the observed function as a transformation
inhibitor. Additionally, this apparent tumor suppressive activity
did not correlate with the pro-vitamin A potential of these
particular carotenoids [80] as might have been expected from the
similar influence of retinoids and carotenoids on Cx43
expression. Indeed, recent studies have shown that these two
classes of chemopreventive agents induce Cx43 expression by
different mechanisms. Gene induction at the level of protein and
mRNA by retinoids but not carotenoids is inhibited by
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receptors (RARs). In contrast, induction by non-pro-vitamin A
carotenoids is inhibited by antagonists of the peroxisome
proliferator activated nuclear receptors (PPAR) [81].
11. Problems confronting use of carotenoids as
chemopreventive agents
Carotenoids are highly lipophilic molecules and are poorly
and variably adsorbed after human ingestion. Additionally
some carotenoids, particularly h-carotene, may become pro-
oxidants under conditions of high oxygen tension such as
found in the lung. Under these conditions, as first described by
Burton and Ingold [68], the initial reaction with oxidant
produces an unstable intermediate which can itself react with
unsaturated lipids for example, to produce a chain reaction
resulting in the formation of additional reactive species such as
epoxides and carbonyl compounds. The biological significance
of this phenomenon is unclear, but may be in part responsible
for the increased lung cancer rates observed in intervention
trials conducted with high-dose h-carotene in smokers and
asbestos-exposed individuals [65,82]. Cell constituents are
confronted with multiple sources of highly-reactive oxidative
species capable of causing lipid peroxidation and DNA
damage. Fortunately, not all carotenoids become pro-oxidants
under these conditions, astaxanthin (ASTX, 3,3V-dihydro-4,4V-
diketo-h-carotene), has been described as a more potent
antioxidant than h-carotene yet does not demonstrate pro-
oxidant activity under high oxygene partial pressure [83]. In
order to overcome the clinical problems associated with
carotenoid drug delivery and possible pro-oxidant toxicity,
Hawaii Biotech Inc. (HBI, Aiea, HI) has developed novel
carotenoid derivatives: including a disodium disuccinate
derivative of ASTX (CARDAXi) [84,85] and a diphosphate
ASTX derivative [86] (Fig. 5). Both compounds form pseudo-
solutions in water at concentrations of up to 8 mg/ml
(CARDAXi) and 25 mg/ml (diphosphate ASTX). Dispersi-
bility is achieved in aqueous solution secondary to self-
assembly of disodium disuccinate ASTX monomers into
supra-molecular complexes. Monomeric solutions of com-
pound can also be achieved by the inclusion of ethanol (EtOH)
at concentrations up to 50%, thereby disrupting this self-
assembly while preserving aqueous solubility [87].
11.1. Water-dispersible derivatives of ASTX upregulate Cx43
expression in 10T1/2 cells and potently inhibit neoplastic
transformation
Development of these water-soluble compounds at Hawaii
Biotech, Inc. has overcome the problems associated with
delivery of dietary carotenoids to biological systems which
required either tetrahydrofuran as solvent or use of a beadlet
formulation (currently available for only three specific car-
otenoids). To determine if the disuccinate ASTX derivative
CARDAXi had potential activity as a chemopreventive, we
treated 10T1/2 cells with various formulations of CARDAXi.
To enhance both solubility and bioavailability, several EtOH/water formulations were tested for aggregation with UV/vis
spectroscopy. The ‘‘solubility’’ of the derivatives was signifi-
cantly enhanced by the use of 1:1 (50% EtOH) and 1:2 (33%
EtOH) EtOH/water formulations. These formulations have
been previously demonstrated to maintain the carotenoid
derivatives in monomeric form [88]. Induction levels of
Cx43, as determined by immuno-blotting, were higher with
the EtOH formulation at 105 M than for formulations in sterile
water alone, demonstrating enhanced biological availability
using EtOH as a co-solvent as suggested by previous physico-
chemical studies. The mixture of stereoisomers of CARDAXi
in pure aqueous formulation was able to upregulate Cx43
expression with equivalent or greater potency than that
previously observed for other carotenoids in organic vehicle
[75]. Importantly, treated cells were found to assemble Cx43
into immunoreactive plaques in regions of cell/cell contact,
consistent with gap junction formation. This was confirmed by
functional studies utilizing a dye-microinjection technique,
which demonstrated that treated cells were more extensively
coupled than solvent-alone control treated cells [84]. We have
recently reported that the diphosphate ASTX derivative also
upregulates Cx43 expression and is capable of completely
suppressing carcinogen-induced 10T1/2 cell transformation at a
concentration of 106 M, making it the most potent carotenoid
we have tested in this assay [86]. The chemopreventive abilities
of these compounds have not yet been explored in animal
studies.
12. Connexins and chemotherapy
12.1. Exploitation of GJC for therapy: the ‘‘bystander effect’’
In this context, the ‘‘bystander effect’’ refers to the ability of
mutant or transfected cells to modulate the behavior of
surrounding cells (bystanders). First noticed in cell cultures
used to study induced mutations conveying resistance to
ouabain or to 5-aza-guanidine, it was discovered that in the
former instance, wild-type cells surrounding mutant cells were
capable of rescuing the mutants from toxicity [89]. This
phenomenon is now known to be due to the reciprocal transfer
of sodium and potassium ions, and occurs only when these
neighboring cells are in junctional communication. Because
ouabain poisons the sodium/potassium ATP pump and leads to
cell death, it was apparent that the mutant cells were capable of
taking over the functions of the poisoned enzyme in the wild-
type cells (termed the ‘‘kiss of life’’). In the second example,
the inverse phenomenon appeared; wild-type cells poisoned the
communicating adjacent mutant cells which would normally
not be susceptible to the cytotoxic drug. This was called the
‘‘kiss of death’’ where cytotoxicity resulted from the transfer of
phosphorylated 5-aza-guanine from Wild-type cells through
gap junctions to mutant cells incapable of phosphorylating 5-
aza-guanine to its active cytotoxic metabolite. Since the
phosphorylated nucleotide is charged, it cannot normally pass
through the plasma membrane and can only gain access to
mutant cells if those cells are in direct junctional communica-
tion. This ability of communicating cells to transfer lethal
T.J. King, J.S. Bertram / Biochimica et Biophysica Acta 1719 (2005) 146–160156metabolites has been exploited in experimental cancer chemo-
therapy, unfortunately, clinical trials using this methodology
have yielded limited success [90].
While this type of experimental therapy has been most
extensively employed to treat gliomas, recently, attention has
also been given to treatment of ovarian carcinoma and
melanoma, all tumors notoriously difficult to treat by conven-
tional chemotherapy or radiotherapy. Here, gene therapy relies
on the ability of viral vectors to deliver the herpes simplex
version of the gene thymidine kinase (HSV-tk) to implanted
tumors followed by treatment of patients with the anti-viral
drug ganciclovir (GCV) (Fig. 7). Mammalian cells cannot
phosphorylate GCV to a cytotoxic nucleotide; however,
herpes-infected cells, or in this case cells transfected with
HSV-tk, are able to phosphorylate the drug to an active
cytotoxic metabolite. The ‘‘bystander effect’’ was evident by
the observation that the number of cells killed was several fold
higher than the number of cells successfully transfected with
the herpes transgene. Subsequently, it was discovered that this
phenomenon was directly correlated with the extent of GJC
between transfected tumor cells and surrounding non-trans-
fected cells and is attributed, as in the earlier observations with
mammalian HGPRT mutants, to the transfer of cytotoxic,
charged nucleotides (GCV) through gap junctions [91].
Clinical failure of this novel therapy is probably a result of
the notoriously inefficient delivery of viral vectors to solid
tumors. In an attempt to circumvent problems of gene delivery,
the use of genetically engineered cells has been explored. As an
example, neural stem cells, which are known to be capable of
extensive migration through the brain, were stably transfected
with HSV-tk and mixed with primary or established cultures of
human glioma cells. Approximately one transfected cell was
shown to be capable of killing ten tumor cells; an effect
dependent upon cell/cell contact and proportional to the
expression of Cx43 in the glioma cells [92]. Factors limiting
this ‘‘bystander effect’’ include the limited ability of most
glioma cells to synthesize Cx43 and thus participate in GJC,
and the limited production of HSV-tk protein by transfectedFig. 7. ‘‘Bystander Effect’’. Left panel denotes a group of surviving (blue) GJC-neg
herpes simplex virus-thymidine kinase (HSV-tk) transgene. Delivery of ganciclovir
activation of GCV to a cytotoxic agent resulting in the death of only the transfect
transfected cells and the cell transfected with HSV-tk allows transmission of the
propagation of cell death among ‘‘bystander’’ cells (right panel).cells. Recently, use of the histone deacetylase inhibitor 4-
phenylbutyrate has been shown to enhance both Cx43 and
HSV-tk expression in transfected glioma cells. This combined
effect resulted in a dramatic increase in the ‘‘bystander effect’’,
i.e., more efficient killing of HSV-tk negative glioma cells [93].
As discussed previously, most tumor cells appear to down-
regulate Cx43 expression as a result of DNA methylation and
gene silencing. Since histone deacetylation is strongly linked to
DNA methylation, it would appear that expression of both
genes (endogenous Cx43 and the transfected viral gene) was
most likely being inhibited by epigenetic mechanisms.
A variation of this approach has recently been explored as a
potential treatment for ovarian cancer. This cancer is known to
extensively metastasize to the abdominal cavity resulting in
very poor prognosis. These investigators, utilized mesothelial
cells, which are easily harvested from human peritoneal
cavities, are known to be capable of forming viable cell
colonies on reinjection into the peritoneal cavity and, impor-
tantly, are capable of directly interacting with ovarian
carcinoma cells. Human mesothelial cells, genetically engi-
neered to express HSV-tk, were shown to be capable of killing
human ovarian carcinoma cells in culture and in a xenograft
mouse model resulting in increased life span in xenografted
mice when exposed to GCV [94]. This offers the interesting
prospect of utilizing isologous mesothelial cells to deliver a
cytotoxic metabolite to peritoneal metastases, thus avoiding use
of immunogenic cells or plasmids. However, distant metastases
would not be affected.
13. GJC as a therapeutic target
In earlier sections of this chapter, we have described that GJC
is extensively downregulated in the vast majority of human
tumors. Moreover, in the experiments in which GJC has been
reestablished by expression of exogenous Cx43 genes, the
neoplastic phenotype of these human and animal cells has been
strongly inhibited. In cell culture, this is most apparent as a
dramatic decrease in anchorage-independent growth; in vivo thisative tumor cells where only the center cell has been stably transfected with the
(GCV, middle panel) in the presence of HSV-tk results in the phosphorylation/
ed, HSV-tk+ cell (orange). Restoration of Cx43 expression/GJC between non-
cytotoxic GCV molecule throughout the communicating tumor resulting in
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other tumor suppressor genes, downregulated expression of
connexins appears most frequently as a consequence of gene
silencing through DNA methylation. As we [24] and several
other investigators have shown, use of histone deacetylase
inhibitors, or of 5-aza-cytidine, an inhibitor of DNA methyla-
tion, either singly or in combination, causes re-expression of
silenced genes including connexins. If this could be achieved
clinically, this might cause the dramatic decrease in tumor
growth rates observed experimentally after forced expression of
connexin genes.
A second approach would be to use the growth suppressive
effects of GJC to inhibit the growth of micrometastases. This has
been shown to be effective in cell culture and in one
experimental animal model of lung metastasis. This approach
also requires the presence of a pharmacological agent to restore
GJIC between tumor cells and normal cells. Here, drug treatment
employs agents that inhibit cyclic AMP phosphodiesterase
(cAMP-PDE) thereby elevating intracellular levels of cAMP.
This phenomenon was first demonstrated in co-cultures of non-
transformed mouse 10T1/2 cells and malignantly transformed
derivatives of this cell line. In the control situation, when
transformed cells are allowed to attach to the growth-inhibited
monolayer of normal cells, the transformed cells are capable of
colony formation and progressively invade the normal mono-
layer. However, if cultures are treated simultaneously with
cAMP-PDE inhibitors, the malignant cells attach but fail to
proliferate for as long as drug treatment is maintained. Upon
withdrawal, cells rapidly reenter the cell cycle and proceed to
invade the normal cells [95]. The extent of growth inhibition was
shown to be directly proportional to the degree with which the
two cell types were in junctional communication [96]. 10T1/2
cells are known to express Cx43 whose C-terminal tail contains
multiple serine phosphorylation sites known to be essential for
functional communication, and it must be assumed, but this has
not been demonstrated, that elevated cAMP levels increase the
phosphorylation state of crucial serine residues.
Inhibition of lung metastasis was observed in an experi-
mental mouse model involving the highly metastatic Lewis
lung carcinoma cell line. In the control situation, after either
intravenous injection of these cells or after spontaneous
shedding from a transplanted intramuscular tumor, carcinoma
cells rapidly form discrete lung metastases which can be readily
quantified. However, when animals were treated with the same
cAMP-PDE inhibitors shown to inhibit growth of both
transformed 10T1/2 cells and Lewis lung carcinoma cells
when in co-culture with growth inhibited normal cells, lung
metastases were virtually abolished for the duration of drug
treatment. Following drug removal, as in the cell culture
studies, tumor cells rapidly grew to form macroscopic
metastases [97]. Pathological analysis of lungs of treated
animals revealed the presence of micrometastases which were
clearly unable to proliferate. By using pulse-chase radiolabeled
thymidine, we were able to show that these carcinoma cells
were growth arrested with a prolonged G1/G0 cell cycle phase
[98]. While this approach does not eliminate the tumor cells, it
prevents their growth to form life-threatening metastases asshown by the dramatic increase in life span of treated animals.
If this were translated clinically, it could be used to prevent the
proliferation of tumor cells released from the primary tumor at
time of surgery, for example, until a time when the patient may
be better able to withstand conventional chemotherapy. At this
time treatment with the cAMP-PDE inhibitor would be
withdrawn, tumor cells would rapidly enter the cell cycle and
then become susceptible to currently available cycle-specific
therapeutic agents.
14. Concluding remarks
The consistent demonstration of loss of functional GJC as a
consequence of abnormal expression or aberrant processing of
connexins, together with data showing that restoration of GJC
reduces the neoplastic potential of human and animal cancer
cells, clearly establishes connexins as tumor suppressor genes.
Importantly, increased tumor susceptibility in mice deficient for
particular connexins further supports the proposed tumor
suppressor role of connexins and GJC. In pre-malignant cells,
reduced expression may be normalized by chemopreventive
agents such as the retinoids or carotenoids. Here, restoration of
GJC may also restore growth control. However, in fully
malignant cells containing multiple mutations, restoration of
GJC appears to require either forced expression of connexins
by gene transfer or use of drugs to hypo-methylate silenced
endogenous connexin genes. Frequently, in cell culture,
malignant cells appear to loose only the most advanced aspects
of the malignant phenotype; anchorage-independent growth
and growth as xenografts. The mechanism by which connexins
modify cell behavior is incompletely understood and may lead
to the identification of novel pathways and novel targets for
prevention and therapy. The exploitation of GJC to allow the
selective transfer of toxic metabolites to target cancer cells,
described as the ‘‘bystander effect’’, is a promising develop-
ment in cancer therapy that will also benefit from an increased
mechanistic understanding of connexin gene expression
regulation.
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